Clinical Trial Results: An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 [Phase 3]

View source ↗

Summary

Phase 3 open-label study results for non-responders to VRDN-001-101 and VRDN-001-301 in Thyroid Eye Disease have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Eye Disease

Drugs mentioned

• VRDN-001

Snippet

Sponsor: Viridian Therapeutics, Inc. | Conditions: Thyroid Eye Disease | Phase 3 | Status: COMPLETED | Results posted: 2026-08-14